CARPHA > VigiCarib

VigiCarib

> >

Contact

For more information or submission of inquiries:
CRSRegistration@carpha.org
For more background and context, please see the recent article published in the Pan American Journal of Public Health.
Regionalization as an approach to regulatory systems strengthening: a case study in CARICOM Member States

VigiCarib (Pharmacovigilance and Post Market Surveillance)

VigiCarib is a voluntary regional system for CARICOM states to report medicines related adverse events (adverse drug reactions (ADRs)) and substandard and falsified (SF) products. Medicines safety and monitoring systems are often limited in the individual small states of CARICOM, and the rationale for a regional approach is that with pooling of resources, sharing of information, and coordination of activities, there will be efficiencies of scale that can lead to stronger systems overall.

Supporting Global Vigilance and Post-market Surveillance:

VigiCarib network facilitates the submission of reports of suspected adverse drug reactions (ADRs), and reports of quality issues to international monitoring systems of the WHO Programme for International Drug Monitoring at Uppsala Monitoring Centre, and to the WHO Global Surveillance and Monitoring System. This assists Member States with limited human resources to contribute to global vigilance, and to receive information on international and regional trends in reporting.

Reporting Forms:

Reports of suspected adverse drug reactions, and reports of suspect substandard / falsified / unregistered medicines may be submitted confidentially to VigiCarib using any of the following methods:

The VigiCarib Reporting form in Word;

The VigiCarib Online Form at: https://form.jotform.co/72934157245864; or

E-Reporting (for reports of suspected adverse drug reactions from St Vincent and the Grenadines): https://primaryreporting.who-umc.org/Reporting/Reporter?OrganizationID=VC

Pharmacovigilance in Member States:

Additional information on pharmacovigilance and post-market surveillance in some Member States may be found at the following sites:

Barbados: Reporting Forms for Barbados Drug Service at: http://drugservice.gov.bb/
Belize: Regional Portal for online notification of suspicion of adverse reactions to medicinal products for human use (Noti-FACEDRA): http://www.notificacentroamerica.net/n/Pages/mapa.aspx
Belize: Identifying and Reporting Substandard and/or Falsified Products: http://health.gov.bz/www/units/drug-inspectorate-unit/post-market-surveillance
Jamaica: Pharmacovigilance at Ministry of Health and Wellness, Division of Standards and Regulation: https://www.moh.gov.jm/divisions-agencies/divisions/standards-and-regulation-division/pharmacovigilance/
Organization of Eastern Caribbean States: Information on Pharmacovigilance and Adverse Reaction reporting: https://www.oecs.org/en/
Trinidad and Tobago: Ministry of Health Chemistry Food and Drug Division, Online Reporting Form: http://www.health.gov.tt/sitepages/default.aspx?id=93

Collaboration with MQCSD:

The CRS works in collaboration with the Medicines Quality Control and Surveillance Department (here) in its post-market surveillance functions. Through the VigiCarib network reports of substandard and/or falsified medicines identified in Member States are shared with the MQCSD, and focal points are encouraged to contact the department for information on testing. In addition, when products are found to be substandard or falsified when tested by the MQCSD, the Member State is encouraged to share this in the network.